| Literature DB >> 12404160 |
Daniel F Hoft1, Shewangizaw Worku, Beate Kampmann, Christopher C Whalen, Jerrold J Ellner, Christina S Hirsch, Robin B Brown, Rhonda Larkin, Qing Li, Hyun Yun, Richard F Silver.
Abstract
Tuberculosis (TB) vaccine development is hindered by the lack of clear surrogate markers of protective human immunity to Mycobacterium tuberculosis. This study evaluated the hypothesis that immune-mediated inhibition of mycobacterial growth would more directly correlate with protective TB immunity than other immunologic responses. Bacille Calmette-Guérin (BCG) vaccination, known to induce partial protection against TB, was used as a model system to investigate mechanistic relationships among different parameters of antigen-specific immunity. Effects of primary and booster intradermal BCG vaccinations were assessed in 3 distinct assays of mycobacterial inhibition. Correlations between vaccine-induced growth inhibition and other immune responses were analyzed. BCG significantly enhanced all antigen-specific responses. Peak responses occurred at 2 months after boosting. Statistical analyses suggested that each assay measured unique aspects of mycobacterial immunity. Despite previous evidence that type 1 immune responses are essential for TB immunity, interferon-gamma production did not correlate with mycobacterial inhibition. These results have important implications for TB vaccine development.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12404160 DOI: 10.1086/344359
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226